EditorialsRET Mutations in Neuroendocrine Tumors: Including Small-Cell Lung Cancer
Under an Elsevier user license
open archive
Cited by (0)
Dr. Rudin has been a paid consultant regarding cancer drug development for AbbVie, Aveo, Celgene, GlaxoSmithKline, and Merck. Dr. Drilon has been a paid consultant regarding cancer drug development for Exelixis. Dr. Poirier has no conflicts of interest.
Copyright © 2014 International Association for the Study of Lung Cancer. All rights reserved.